Virion Therapeutics Reports Durable Functional Cure Signals in Chronic Hepatitis B with Single-Dose VRON-0200 at EASL 2026 Virion Therapeutics, LLC, a clinical-stage biotechnology company focused on developing next-generation T cell–based immunotherapies for chronic viral diseases, has announced compelling long-term clinical…
Bristol Myers Squibb’s Mezigdomide Combo Shows Strong Phase 3 Success in Relapsed Multiple Myeloma at ASCO 2026 Bristol Myers Squibb has announced encouraging late-breaking results from the Phase 3 SUCCESSOR-2 clinical trial evaluating its investigational CELMoD therapy mezigdomide in combination…
BeOne Medicines Showcases Long-Term BRUKINSA Success and Next-Generation CLL Treatment Advances at ASCO 2026 BeOne Medicines Ltd., a global oncology company dedicated to developing innovative cancer therapies, is presenting extensive new data at the 2026 American Society of Clinical Oncology…
Otsuka Pharmaceutical Development & Commercialization Presents New Phase 3 Centanafadine Analyses Highlighting Broader ADHD Symptom Improvements Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Development & Commercialization unveiled new post hoc exploratory analyses from two pivotal Phase 3 clinical studies evaluating…
PharmaEssentia Names Eric Vogel as U.S. Commercialization Head in Preparation for Potential BESREMi® Launch in Essential Thrombocythemia PharmaEssentia Corporation has announced the appointment of Eric Vogel as the company’s new U.S. Head of Commercialization, strengthening its leadership team as it…
Stallergenes Greer Foundation Honors Advances in Allergy Innovation Through 2025 Award Program Stallergenes Greer Foundation has announced the recipients of its 2025 Science Awards for Allergy, recognizing four researchers whose work is helping advance the understanding, diagnosis, and treatment of…
Agilent Technologies Introduces Advanced Multi-Attribute Method Solution to Streamline BioPharma Quality Control and Analytical Testing Agilent Technologies has announced the launch of a new multi-attribute method (MAM) workflow designed to help pharmaceutical and biopharmaceutical quality control laboratories adopt liquid chromatography…
Curi Bio Unveils Curiverse™ at MPS 2026, the First Closed-Loop Platform for Human-Relevant Drug Discovery Curi Bio has officially unveiled the Curiverse™ at the Microphysiological Systems World Summit 2026, introducing what the company describes as the industry’s first fully integrated…
IDEXX Enhances Fecal Dx™ Antigen Testing Platform with Advanced Taeniid Tapeworm Detection Capability IDEXX Laboratories has announced a significant expansion of its widely used Fecal Dx™ antigen testing platform, introducing new capabilities to detect taeniid tapeworm infections, including parasites from…
Baszucki Group Backs Oxford University Trial Exploring Ketogenic Therapy for Early Psychosis Baszucki Group has announced a £1.17 million grant to support a pioneering clinical trial at the University of Oxford aimed at evaluating whether a ketogenic diet could help…
ClearNote Health to Present New Validation Data for Avantect Pancreatic Cancer Test at ASCO 2026 ClearNote Health has announced that it will present new multi-cohort validation data for its Avantect Pancreatic Cancer Test during the ASCO Annual Meeting 2026, which…
Vyriad has introduced G-Link, a modular platform designed to enhance T-cell targeted lentiviral vector delivery for both in vivo and ex vivo therapeutic applications. Vyriad, Inc. has introduced a new modular adaptor protein technology called G-Link™, a platform designed to…